This trial is active, not recruiting.

Conditions endometrial thickness, pregnancy outcome
Treatment hcg (human chorionic gonadotropin)
Phase phase 4
Sponsor Universitair Ziekenhuis Brussel
Collaborator Human Reproduction & Genetics Foundation
Start date January 2012
End date December 2013
Trial size 15 participants
Trial identifier NCT01768247, THINENDOM001


A thin endometrium is one of the most difficult problems encountered in assisted reproduction every day practice Regarding the proliferative phase, several ways of treatment have been undertaken to circumvent thin endometrium trying to increase thickness with questionable results.

The objective of the current study will be whether a daily dose of 150 IU (international units) of human chorionic gonadotropin (HCG) for seven days concomitant with estrogen administration in estrogen replacement cycles can increase the endometrial thickness and improve pregnancy outcome.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
hcg (human chorionic gonadotropin)
150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement

Primary Outcomes

Endometrial thickness
time frame: 14 days after estrogen treatment

Secondary Outcomes

Pregnancy outcome
time frame: 5 weeks after embryotransfer

Eligibility Criteria

Female participants from 30 years up to 50 years old.

Inclusion Criteria: - (1) Less than 6mm endometrial thickness before, (2) at least two failed implantations before Exclusion Criteria: - Abnormal uterine cavity in Hysteroscopy

Additional Information

Official title HCG Priming for Thin Endometrium in IVF
Principal investigator Papanikolaou Evangelos, MD
Description In this pilot study subjects with repeatedly resistant thin endometrium, less than 6mm, will be recruited. The investigators sought to investigate the possible role of adding low dose HCG in the follicular phase, on the endometrial growth and development. The investigators constructed this hypothesis based on the fact that LH/HCG (luteinizing hormone/human chorionic gonadotropin) receptor is present in endometrium and therefore a positive interaction could be anticipated when HCG is administered in the proliferative phase of endometrial growth. Furthermore, in a previous study, where human menopausal gonadotropin (hMG) -well known that renders its luteinizing hormone (LH) capacity due to low dose HCG contain- was compared to recombinant-follicular stimulating hormone (rec-FSH) during ovarian stimulation, endometrium was more likely to be iso-echogenic and hypo-echogenic in the hMG group, also anticipating a possible positive role of HCG activity.
Trial information was received from ClinicalTrials.gov and was last updated in January 2013.
Information provided to ClinicalTrials.gov by Universitair Ziekenhuis Brussel.